The impact of Hepatocellular Carcinoma at Counties Manukau Health
McGouran D, Counties Manukau District Health Board
Galssey E, Brickland T, Gerred S
Introduction: The incidence of Hepatocellular (HCC) is rising in New Zealand and is driven by the increasing burden of advanced liver disease. Intervention for HCC has become commonplace over the last decade. Unfortunately there are high rates of recurrent and metachronous tumours. We document the rates of diagnosis, interventions, and outcomes for HCC over the last 15 years at CMH.
Methods: A prospective database of new cases of HCC has been kept since 2000.The electronic patient records were reviewed.
Results: 261 patients were diagnosed with HCC between 2000 and 2015. Recurrent or metachronous tumours were identified in 35% (91). The majority were male (78%), median age at first diagnosis was 60 years. Maori, Asian, and Pacific patients accounted for 73% as Hepatitis B, the leading underlying aetiology for HCC, is endemic in these ethnic groups (fig1). The numbers diagnosed each year and the primary intervention undertaken is displayed in figure 2.